Abstracts Archive - Page 1623 of 2425 - ACR Meeting Abstracts

Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Philip G. Conaghan¹, Michael A Bowes², Mikkel Østergaard³, Gwenael Guillard², Douglass Chapman⁴, Amy Stein⁵, John Andrews⁴, Zhiyong Xie⁶, Andrew Koenig⁷, Koshika Soma⁴ and Bethanie Wilkinson⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Pfizer Inc, New York, NY, ⁵Biostatistics, Quintiles, Morrisville, NC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…
Abstract Number: 3091 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Neil Graham⁴, Anne Barbot⁵, Moshe Zilberstein³ and Anita Boyapati⁴, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France
Background/Purpose: Patients with RA develop bone and joint damage due to chronic inflammation that is mediated by a destructive synovial pannus.1 The pannus is composed…
Abstract Number: 3092 • 2016 ACR/ARHP Annual Meeting
Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Kazuyoshi Saito¹, Kazuhisa Nakano², Shingo Nakayamada³, Satoshi Kubo⁴, Ippei Miyagawa¹, Shigeru Iwata⁵ and Yoshiya Tanaka⁶, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Eight biologics have been approved for rheumatoid arthritis (RA) in Japan. However, little is known regarding what to do when patients have an inadequate…
Abstract Number: 3093 • 2016 ACR/ARHP Annual Meeting
Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial
Alexandre Virone¹, Jean-Philippe Bastard², Soraya Fellahi², Jacqueline Capeau², Stéphanie Rouanet³, Jean Sibilia⁴, Philippe Ravaud⁵, Francis Berenbaum⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam⁶, ¹Rheumatology, Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ²APHP Hôpital Tenon, Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, DHU i2B, Paris, France, ³StatEthic, Levallois-Perret, France, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Hôpital Hôtel Dieu, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Considering the increased cardiovascular risk in RA patients and the influence of biologics, especially tocilizumab (TCZ) on the lipid profile, we aimed to investigate…
Abstract Number: 3094 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
Yinzhu Jin¹, Rishi J. Desai¹, Jun Liu¹, Nam-Kyong Choi¹ and Seoyoung Kim^2,3, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospita and, Harvard Medical School,, Boston, MA
Background/Purpose: Treatment with disease-modifying antirheumatic drugs (DMARDs) is considered the standard of care for rheumatoid arthritis (RA). Over the past two decades, major advances have…
Abstract Number: 3095 • 2016 ACR/ARHP Annual Meeting
What Should be the Primary Target of ‘Treat to Target’ in Psa?
Laura C. Coates^1,2, Paul Emery³, Philip G. Conaghan¹ and Philip S. Helliwell¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In 2013, Treat to Target (T2T) in SpA Recommendations by expert consensus stated that the target of treatment should be remission or inactive disease.…
Abstract Number: 3096 • 2016 ACR/ARHP Annual Meeting
Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample
Paras Karmacharya¹, Dilli Poudel¹, Rashmi Dhital² and Pragya Shrestha³, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Universal College of Medical Sciences, MBBS, Kathmandu, Nepal, ³Internal medicine, Reading Health System, West Reading, PA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis affecting approximately 520,000 patients in the US and up to one third of patients with psoriasis. Studies…
Abstract Number: 3097 • 2016 ACR/ARHP Annual Meeting
Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort
Ralf G. Thiele¹, Yahui Grace Chiu², Francisco Tausk³, Bethany A. Marston⁴, Changyong Feng⁵, Gregory Dieudonne⁶, Vaseem Chengazi⁶, Sharon Moorehead⁷, Debbie Campbell⁷ and Christopher T. Ritchlin⁸, ¹Medicine, University of Rochester Medical Center, Rochester, NY, ²Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Dermatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Radiology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁸Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by an average of 10 years psoriatic arthritis (PsA) patients. Reports have demonstrated abnormal musculoskeletal imaging findings in psoriasis…
Abstract Number: 3098 • 2016 ACR/ARHP Annual Meeting
The Occurrence of Peripheral Arthritis Mutilans in Psoriatic Arthritis Is Associated with Certain Major Histocompatibility Class I Alleles
Jon T. Giles¹, Deepak R. Jadon², Muhammad Haroon³, Jing Bi⁴, Eleanor Korendowych², William Tillett², Oliver FitzGerald⁵, Robert Winchester⁴ and Neil J. McHugh², ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Several human leukocyte antigen (HLA) Class I loci encoding the major histocompatibility complex (MHC) have been implicated both in psoriatic arthritis (PsA) susceptibility and…
Abstract Number: 3099 • 2016 ACR/ARHP Annual Meeting
Higher Prevalence and Severity of Coronary Atherosclerosis in Psa Patients
Lydia Ho Pui TAM^1,2, Tsz Ho CHENG¹, Ho Man LAM¹, Ka Tat WONG³, Qing SHANG⁴, Edmund LI¹, Wang Kit LI⁵, Man Fei CHEUNG⁵, Uen-Lam MING¹, Tin-Long LUI⁵, Wing-Lam TAO¹, SY TSANG¹ and Lai-Shan TAM⁶, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, ³Prince of Wales Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Patients with psoriatic arthritis (PsA) have increased risk in cardiovascular diseases (CVD) including subclinical atherosclerosis. However, previous knowledge was limited to carotid atherosclerosis. The…
Abstract Number: 3100 • 2016 ACR/ARHP Annual Meeting
Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Prospective Cohort Study in Psoriatic Arthritis
Tsz Ho CHENG¹, Qing SHANG², PW Alex LEE¹, Priscilla WONG¹, Tracy Y. ZHU³, Chun-Kwok WONG⁴, JW Jack LEE⁵, M Mimi CHANG⁶, Edmund LI¹ and Lai-Shan TAM⁷, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Patients with PsA were reported to have a higher incidence of cardiovascular disease (CVD) and subclinical carotid atherosclerosis due to underlying inflammation. Minimal disease…
Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting
Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Yenealem Temesgen-Oyelakin², Maureen Sampson³, Aditya Joshi⁴, Alice Fike⁵, Michael Davis⁶, Taufiq Salahuddin⁷, Balaji Natarajan⁷, Joseph Lerman⁷, Zerai G. Manna⁸, Amit Dey⁹, Marcus Chen⁷, Sarfaraz Hasni⁸, Nehal N. Mehta⁷, Alan Remaley⁷ and Mariana Kaplan¹⁰, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹National Institutes of Health, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD
Background/Purpose: The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…
Abstract Number: 3102 • 2016 ACR/ARHP Annual Meeting
Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Aditya Joshi³, Joseph Lerman⁴, Michael Davis³, Alice Fike⁵, Amit Dey⁶, Taufiq Salahuddin⁷, Balaji Natarajan³, Martin P. Playford⁷, Heather Teague³, Zerai G. Manna⁵, Marcus Chen³, Sarfaraz Hasni⁵, Nehal N. Mehta⁷ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Clinical Center, NIH, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, when compared…
Abstract Number: 3103 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Prevalent Cardiovascular Disease in African American Systemic Lupus Erythematous Patients
Ashira Blazer¹, Robert M Clancy², H. Michael Belmont³, Peter M. Izmirly³, Androo Markham⁴ and Jill P. Buyon⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, located on chromosome 22q12.3, have been associated with excess renal risk in African Americans…
Abstract Number: 3104 • 2016 ACR/ARHP Annual Meeting
Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis
Michelle Lopes¹, Luciana Seguro¹, Maite Castro², Danielle Daffre³, Eduardo Ferreira Borba² and Eloisa Bonfa⁴, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ³São Paulo University, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: Treat to target strategies are becoming the best approach for several rheumatic disorders. Recently retrospective analyses of two important lupus trials have reported that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].